NEW YORK, NY / ACCESSWIRE / August 12, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
ProAssurance Corporation (NYSE:PRA)
Investors Affected : April 26, 2019 - May 7, 2020
A class action has commenced on behalf of certain shareholders in ProAssurance Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) ProAssurance lacked adequate underwriting process and risk management controls necessary to set appropriate loss reserves in its Specialty P&C segment; (ii) ProAssurance failed to properly assess a large national healthcare account that experienced losses far exceeding the assumptions made when the account was underwritten; and (iii) as a result, ProAssurance was subject to materially heightened risk of financial loss and reserve charges.
Shareholders may find more information at https://securitiesclasslaw.com/securities/proassurance-corporation-loss-submission-form/?id=8521&from=1
Chembio Diagnostics, Inc. (NASDAQ:CEMI)
Investors Affected : March 12, 2020 - June 16, 2020
A class action has commenced on behalf of certain shareholders in Chembio Diagnostics, Inc. According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.
Shareholders may find more information at https://securitiesclasslaw.com/securities/chembio-diagnostics-inc-loss-submission-form/?id=8521&from=1
Co-Diagnostics, Inc. (NASDAQ:CODX)
Investors Affected : February 25, 2020 - May 15, 2020
A class action has commenced on behalf of certain shareholders in Co-Diagnostics, Inc. According to the filed complaint, Co-Diagnostics and its directors and officers (including PhD-level scientists who should know better) made continual, knowing, and willful misstatements about the Company's main product, a Covid-19 diagnostic test. These misstatements had the effect of pumping up the price of Co-Diagnostics' stock while Company officers and directors exercised low-priced options and dumped their stock into the market. Co-Diagnostics' fraudulent misstatements displayed a disregard for basic scientific principles and caused investors to lose millions of dollars.
Shareholders may find more information at https://securitiesclasslaw.com/securities/co-diagnostics-inc-loss-submission-form/?id=8521&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com:
https://www.accesswire.com/601405/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-PRA-CEMI-and-CODX
